Sage Therapeutics, Inc. - stock earnings
SAGE Upcoming estimated earnings
| Date | Actual / Estimated EPS | Low Revenue | Actual / Estimated Revenue | High Revenue |
|---|---|---|---|---|
| June 10, 2024 BeforeMarket | - / - | 2.1 million | - / 5.8 million | 15.1 million |
| Aug. 5, 2024 BeforeMarket | - / - | 5.0 million | - / 8.7 million | 13.9 million |
SAGE Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2024Q1 | -108.5 million USD | 7.9 million USD |
| 2023Q4 | -32.7 million USD | 78.0 million USD |
| 2023Q3 | -201.6 million USD | 2.7 million USD |
| 2023Q2 | -160.3 million USD | 2.5 million USD |
| 2023Q1 | -138.2 million USD | 3.3 million USD |
| 2022Q4 | -133.3 million USD | 2.9 million USD |
| 2022Q3 | -129.0 million USD | 1.7 million USD |
| 2022Q2 | -122.0 million USD | 1.5 million USD |
| 2022Q1 | -119.7 million USD | 1.6 million USD |
| 2021Q4 | -124.7 million USD | 1.6 million USD |
| 2021Q3 | -130.2 million USD | 1.4 million USD |
| 2021Q2 | -107.2 million USD | 1.6 million USD |
| 2021Q1 | -95.8 million USD | 1.6 million USD |
| 2020Q4 | 974.9 million USD | 1.1 billion USD |
| 2020Q3 | -105.7 million USD | 1.6 million USD |
| 2020Q2 | -136.3 million USD | 1.1 million USD |
| 2020Q1 | -126.7 million USD | 2.3 million USD |
| 2019Q4 | -168.7 million USD | 2.0 million USD |
| 2019Q3 | -180.0 million USD | 3.6 million USD |
| 2019Q2 | -168.2 million USD | 873000 USD |
| 2019Q1 | -163.4 million USD | 465000 USD |
| 2018Q4 | -158.4 million USD | 273000 USD |
| 2018Q3 | -122.9 million USD | 90.0 million USD |
| 2018Q2 | -17.0 million USD | 90.0 million USD |
| 2018Q1 | -74.6 million USD | ? USD |
| 2017Q4 | -69.4 million USD | ? USD |
| 2017Q3 | -73.7 million USD | ? USD |
| 2017Q2 | -70.2 million USD | ? USD |
| 2017Q1 | -56.8 million USD | ? USD |
| 2016Q4 | -55.9 million USD | ? USD |
| 2016Q3 | -37.8 million USD | ? USD |
| 2016Q2 | -34.7 million USD | ? USD |
| 2016Q1 | -30.5 million USD | ? USD |
| 2015Q4 | -28.6 million USD | ? USD |
| 2015Q3 | -24.0 million USD | ? USD |
| 2015Q2 | -25.0 million USD | ? USD |
| 2015Q1 | -16.9 million USD | ? USD |
| 2014Q4 | -12.4 million USD | ? USD |
| 2014Q3 | -9.5 million USD | ? USD |
| 2014Q2 | -6.2 million USD | ? USD |
| 2014Q1 | -5.8 million USD | ? USD |
| 2013Q4 | -5.7 million USD | ? USD |
| 2013Q3 | -4.5 million USD | ? USD |
| 2013Q2 | -4.7 million USD | ? USD |
| 2013Q1 | -3.4 million USD | ? USD |
SAGE Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -541.5 million USD | 86.5 million USD |
| 2022 | -503.3 million USD | 7.7 million USD |
| 2021 | -450.8 million USD | 6.3 million USD |
| 2020 | 606.1 million USD | 1.1 billion USD |
| 2019 | -650.2 million USD | 6.9 million USD |
| 2018 | -372.9 million USD | 90.3 million USD |
| 2017 | -270.1 million USD | ? USD |
| 2016 | -159.0 million USD | ? USD |
| 2015 | -94.5 million USD | ? USD |
| 2014 | -33.8 million USD | ? USD |
| 2013 | -18.3 million USD | ? USD |
| 2012 | -9.6 million USD | ? USD |
SAGE
Price: $12.90
52 week price:
Payout Ratio Range:
Earnings Per Share: -8.39 USD
P/E Ratio: -2.11
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 427700
Ebitda: -74.2 millionMarket Capitalization: 838.9 million